Pegcetacoplan for Complement 3 Glomerulopathy

This trial tests the effectiveness and safety of Pegcetacoplan for individuals with specific kidney issues, specifically C3G and primary IC-MPGN. The study aims to evaluate the treatment's performance in a real-world setting and to understand its long-term benefits and risks. Individuals already receiving or planning to receive Pegcetacoplan for these conditions can participate. As a Phase 4 trial, this research helps determine how this FDA-approved and proven effective treatment benefits a broader patient population.

Research has shown that pegcetacoplan is generally safe for treating C3 glomerulopathy (C3G). Studies have found it to be well-tolerated in various kidney conditions. For instance, one study reported no serious side effects, indicating that pegcetacoplan was well-received overall. Another study found it did not cause more negative effects than a placebo. Common side effects include mild reactions at the injection site, but serious infections did not occur. Additionally, pegcetacoplan received approval in 2025 for treating C3G and related kidney issues, supporting its safety.¹²³⁴⁵

Unlike the standard treatments for complement 3 glomerulopathy, which often include general immunosuppressants, pegcetacoplan directly targets the complement system. This drug acts specifically on complement component 3 (C3), a part of the immune system that plays a crucial role in this disease. By inhibiting C3, pegcetacoplan aims to prevent the underlying mechanisms that lead to kidney damage, offering a more precise approach than traditional therapies. Researchers are excited about pegcetacoplan because it represents a novel mechanism of action that could provide more effective and potentially less toxic treatment for patients.

Research has shown that pegcetacoplan can significantly reduce excess protein in the urine of patients with C3 glomerulopathy (C3G), a kidney condition. One study reported a 68% reduction in excess protein after 26 weeks, with continued improvement at 52 weeks. Another study found an 81% decrease in excess protein within six months, with most patients showing improvement. Pegcetacoplan also increased levels of a protein called C3 in the blood, suggesting it helps control abnormal immune activity in C3G. Overall, pegcetacoplan has demonstrated strong potential in improving kidney function and managing symptoms of C3G. Participants in this trial will receive pegcetacoplan to further evaluate its effectiveness in treating C3G.³⁶⁷⁸⁹